Considering the fibrotic hallmarks of RDEB identified in the literature, we designed an initial repositioning strategy based on the phenotypic screening of COL7A1-deficient fibroblasts from RDEB patients and focused on these potential biomarkers. This evidence concerns the gene COL7A1 and recessive dystrophic epidermolysis bullosa.